Reports Q1 revenue $116.63M, consensus $57.72M. “The increasing surge in patient prescriptions by doctors across the U.S. shows that the ATTR-CM community believes what we believe – Attruby delivers profound results for patients with separation from placebo in as early as three months, a 42% reduction in all-cause mortality and recurrent hospitalizations, and a 50% decrease in cardiovascular hospitalizations at 30 months,” said Matt Outten, Chief Commercial Officer of BridgeBio (BBIO). “With the approval of BEYONTTRA in the EU, UK, and Japan, acoramidis is well positioned to become the global first line therapy of choice for ATTR-CM.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma options imply 8.2% move in share price post-earnings
- BridgeBio announces UK MHRA marketing authorization for acoramidis
- BridgeBio Pharma: Anticipated Q1 Outperformance and Sustained Buy Rating Despite Rising R&D Expenses
- Buy Recommendation for BridgeBio Pharma Driven by Promising ATTR-CM Launch and Late-Stage Portfolio Potential
- BridgeBio price target raised to $53 from $49 at H.C. Wainwright